Denmark has paid out one-third of Bavarian Nordic's Covid-19 vaccine support
The biotech firm’s development of a Covid-19 vaccine has so far triggered a DKK 240m (USD 33.9m) payment from the Danish state, which set aside a total of DKK 800m (USD 113m) in funding for a Danish vaccine candidate.
by MIKKEL AABENHUS HEMMINGSEN & CHRISTIAN BUNDGAARD, translated by daniel pedersen
Bavarian Nordic’s scheduled initiation of a large phase III trial of its potential Covid-19 vaccine comes as a direct result of the Danish government’s financial support for the development program.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Bavarian Nordic maintains 2022 guidance
For subscribers
